Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Official title

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

Study identification

NCT ID

NCT05554328

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 2

Lead sponsor

National Cancer Institute (NCI)

NIH

Enrollment

165 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

Female

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Apr 24, 2023

Primary completion

Sep 30, 2028

Completion

Sep 30, 2028

Last update posted

May 4, 2026

2023 – 2028

United States locations

U.S. sites

293

U.S. states

36

U.S. cities

233

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.